San Francisco—Gout patients with cardiovascular disease (CVD) could benefit from earlier and more aggressive urate-lowering therapy (ULT), according to a poster presented at the 2016 Academy of Managed Care Pharmacy (AMCP) annual meeting. Failing to ramp up therapy, in contrast, places these patients at heightened risk for severe gout flares and exacerbations of comorbid conditions—a dangerous outcome that pharmacists can help prevent with targeted adjunctive treatment support, the